DNAJC7

Across TCGA pan-cancer cohorts, DNAJC7 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DNAJC7 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher DNAJC7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated DNAJC7 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where DNAJC7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.780	1.000	.004	12	view →
LUAD	OS	Tertile	All	0.540	0.908	.013	9	view →
GBM	DFS	Tertile	All	0.655	0.809	.017	4	view →
PDAC	DFS	Tertile	IV	0.741	0.199	.024	3	view →
HNSC	OS	Tertile	III,IV	0.783	0.549	.030	2	view →
LSCC	DFS	Median	II,III,IV	0.809	0.597	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DNAJC7–CCRCC (OS)

Open the CCRCC breakdown →